Data / Drug companies / Mylan Institutional LLC
Mylan Institutional LLC: 21 products in the FDA NDC directory, labeler code 72078
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Mylan Institutional LLC (labeler code 72078) lists 21 products in the FDA National Drug Code Directory, covering 11 finished drugs by generic name. By type: 21 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on September 1, 2026.
The request: Watch Mylan Institutional LLC (FDA labeler code 72078): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 72078
- Products in commercial distribution
- 21
- Packages
- 20
- Finished drugs by generic name
- 11
- Prescription products
- 21
- Over the counter products
- 0
- Controlled substance products
- Schedule II 3
- Flagged as original packager
- 18 of 18 products that carry the flag
- Started marketing in the last 12 months
- 5
- Earliest marketing start
- November 20, 2020
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 14 | 66.7% |
| New drug applications (NDA) | 7 | 33.3% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 21 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Eptifibatide | 3 | 9 |
| Docetaxel anhydrous | 3 | 5 |
| Remifentanil hydrochloride | 3 | 4 |
| Vancomycin hydrochloride | 2 | 39 |
| Isosulfan blue | 2 | 7 |
| Ferric carboxymaltose | 2 | 3 |
| Calcitonin salmon | 2 | 13 |
| Acetazolamide sodium | 1 | 3 |
| Adenosine | 1 | 15 |
| Amiodarone hydrochloride | 1 | 35 |
| Meropenem | 1 | 17 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection, solution | 13 | 61.9% |
| Injection, powder, lyophilized, for solution | 6 | 28.6% |
| Injection | 2 | 9.5% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Acetazolamide | 72078-092 | Injection, powder, lyophilized, for solution | Generic drugs (ANDA) | September 1, 2026 |
| Ferric Carboxymaltose | 72078-048 | Injection, solution | Generic drugs (ANDA) | August 31, 2026 |
| Ferric Carboxymaltose | 72078-060 | Injection, solution | Generic drugs (ANDA) | July 1, 2026 |
| Isosulfan Blue | 72078-070 | Injection, solution | Generic drugs (ANDA) | February 1, 2026 |
| Isosulfan Blue | 72078-069 | Injection, solution | Generic drugs (ANDA) | February 1, 2026 |
| Meropenem | 72078-081 | Injection | Generic drugs (ANDA) | July 1, 2025 |
| Ultiva | 72078-036 | Injection, powder, lyophilized, for solution | New drug applications (NDA) | December 16, 2024 |
| Vancomycin Hydrochloride | 72078-066 | Injection, powder, lyophilized, for solution | New drug applications (NDA) | July 23, 2024 |
| Vancomycin Hydrochloride | 72078-065 | Injection, powder, lyophilized, for solution | New drug applications (NDA) | July 23, 2024 |
| Ultiva | 72078-035 | Injection, powder, lyophilized, for solution | New drug applications (NDA) | September 18, 2023 |
| Ultiva | 72078-034 | Injection, powder, lyophilized, for solution | New drug applications (NDA) | June 21, 2023 |
| Amiodarone Hydrochloride | 72078-046 | Injection, solution | Generic drugs (ANDA) | June 9, 2023 |
| Docetaxel | 72078-087 | Injection, solution | Generic drugs (ANDA) | August 3, 2022 |
| Docetaxel | 72078-086 | Injection, solution | Generic drugs (ANDA) | August 3, 2022 |
| Docetaxel | 72078-040 | Injection, solution | Generic drugs (ANDA) | August 3, 2022 |
| Miacalcin | 72078-039 | Injection, solution | New drug applications (NDA) | July 18, 2022 |
| Miacalcin | 72078-038 | Injection, solution | New drug applications (NDA) | June 16, 2022 |
| Adenosine | 72078-033 | Injection | Generic drugs (ANDA) | April 6, 2022 |
| Eptifibatide | 72078-027 | Injection, solution | Generic drugs (ANDA) | April 1, 2021 |
| Eptifibatide | 72078-025 | Injection, solution | Generic drugs (ANDA) | April 1, 2021 |
| Eptifibatide | 72078-026 | Injection, solution | Generic drugs (ANDA) | November 20, 2020 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.